BioSpace News Archive

Oramed Pharmaceuticals Inc. announced positive results from the initial cohort of the Phase IIb trial evaluating the efficacy and safety of its lead oral insulin candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsule for the treatment of diabetes.

Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced its recent accomplishments and financial results for the quarter ended September 30, 2019.

BrainStorm Cell Therapeutics, Inc., a leading developer of adult stem cell therapies for neurodegenerative diseases, announced that the Company’s Chief Operating and Chief Medical Officer Ralph Kern MD MHSc will present at the 7th International Stem Cell Meeting, which is hosted by the Israel Stem Cell Society.

Data presented by MD Anderson demonstrates superiority for NBTXR3 activated by radiation therapy and anti-PD-1 in combination versus the radiation therapy and anti-PD-1 combination in an in vivo anti-PD-1-resistant model

Kodiak Sciences Inc., a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, reported business highlights and financial results for the third quarter ended September 30, 2019.

MediPharm Labs Corp. a global leader in specialized, research-driven cannabis extraction, distillation and purification, announced its financial results for the three and nine months ended September 30, 2019.

CompPharma publishes 16th Annual Survey of Prescription Drug Management in Workers’ Compensation

UNAHCO seeks to expand use of OxC-BetaTM Livestock with new application in Broilers, creating new market opportunity for expanded use in a wide variety of feeds worldwide

Reata Pharmaceuticals, Inc. announced financial results for the third quarter ended September 30, 2019, and provided an update on the Company’s business and product development programs.

Solid Biosciences Inc. provided a clinical update on SGT-001 and reported that the U.S. Food and Drug Administration has notified the company that IGNITE DMD, its Phase I/II study of SGT-001, has been placed on clinical hold.